Sequencing and Combining CRPC Therapies - What Does the Future Hold? – Charles Ryan
Chemotherapy in Prostate Cancer- When, Why and How - Fred Saad
A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: EVERYDAY UROLOGY-Full Text Article
Focusing on The First and Only FDA Approved Targeted Alpha Therapy Radium-223 in the Treatment of mCRPC
INTRODUCTION
The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University as a forum for presentations on the latest developments in radiotherapy with alpha emitters in cancer. With over 200 participants the symposium covered advances in cancer treatment using alpha emitters as targeted therapy, clinical and preclinical research, radionuclide production, instrumentation and dosimetry.1
The Multidisciplinary Approach to Prostate Cancer Management: From Diagnosis and Beyond: EVERYDAY UROLOGY- Full Text Article
When patients receive a diagnosis of cancer it can be devastating. Suddenly their world is turned upside down, populated by doctors, diagnostic tests, and treatments.
Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer: EVERYDAY UROLOGY- Full Text Article
Heart disease and cancer are the leading causes of death in the United States.1 Prostate cancer (PC) is the most common cancer in American men, and PC is most frequently diagnosed among men aged 65 to 74 years.2 The American Cancer Society’s estimates for PC in the United States for 2017 are about 161,360 new cases. Of these, about 26,730 are expected to die of the disease.1
Enhanced Recovery After Surgery, Radical Cystectomy and Urinary Diversion: EVERYDAY UROLOGY-Full Text Article
Bladder cancer presents an ever increasing health care burden across the globe. The large majority of patients diagnosed with bladder cancer are over the age of 55, with an average age at the time of diagnosis of 73 and an increasing percentage 80 years and older.1 Men are about three to four times more likely to get bladder cancer during their lifetime than women.1